Article

Risk of Aggressive Skin Cancer Reduced By High Factor Sunscreen

Sunscreen can decrease the risk of melanoma by more than 30%.

The risk of developing melanoma can drop by 33% if high factor sunscreen is used, according to a study published in the Journal of Clinical Oncology.

In the study, individuals who used sunscreen reported more sunburn, more sunbathing vacations, and the use of tanning beds, compared with individuals who never used sunscreen.

As a result, individuals who did not wear sunscreen had a lower risk of developing melanoma than those who used low factor sunscreen. However, earlier studies have shown mixed results, with some of the findings showing a slightly increased risk of melanoma among sunscreen users.

“The explanation for this paradox is that some people use sunscreen for prolong sun exposure and acquire suntan,” said researcher Reza Ghiasvand, PhD. “Moreover, many people don’t apply the proper amount of sunscreen, forget to reapply, and missed to apply on all exposed areas resulting in sunburn and increased risk of melanoma. We found that those who used sunscreen with a factor higher than 15 had a 33% lower risk of melanoma compared with those using sunscreen with a low factor.”

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards